ADVERTISEMENT
Avelumab Significantly Extends OS in Locally Advanced or Metastatic Urothelial Cancer
Avelumab significantly prolonged overall survival (OS) in patients with locally advanced or metastatic urothelial cancer, according to data from a planned interim analysis of the phase 3 JAVELIN Bladder 100 clinical trial.
According to a press statement released by EMD Serono, the multi-center, open-label study comparing the use of first-line avelumab maintenance therapy plus best supportive care with best supportive care alone in 700 patients with urothelial cancer met its primary end point of OS.
Among the patients in the study, all of whom had previously untreated disease that did not progress with induction chemotherapy, avelumab plus best supportive care had significantly longer survival than those who just received best supportive care.
Notably, patients in each of the co-primary populations (ie, all randomized patients and patients with PD-L1–positive tumors) given avelumab plus best supportive care had a statistically significant improvement in OS.
The safety profile observed with avelumab in the JAVELIN Bladder 100 study was consistent with that seen in the JAVELIN monotherapy clinical development program.—Hina Porcelli
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma [news release]. Rockland, MA, and New York, NY: EMD Serono; January 6, 2020. www.prnewswire.com/news-releases/bavencio-significantly-improved-overall-survival-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-300981078.html. January 8, 2020.
